Who Exports Fluticasone from India — 239 Suppliers Behind a $203.0M Market
India's fluticasone export market is supplied by 239 active exporters who collectively shipped $203.0M across 9,009 shipments. CIPLA LIMITED leads with a 91.0% market share, followed by HETERO LABS LIMITED and MEDISPRAY LABORATORIES PRIVATE LIMITED. The top 5 suppliers together control 95.9% of total export value, reflecting a concentrated market structure.
Top Fluticasone Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading fluticasone exporter from India, holding a 91.0% share of the $203.0M market across 9,009 shipments from 239 exporters. The top 5 suppliers — CIPLA LIMITED, HETERO LABS LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, SAVA HEALTHCARE LIMITED — collectively control 95.9% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (91.0%), HETERO LABS LIMITED (2.2%), MEDISPRAY LABORATORIES PRIVATE LIMITED (1.3%), ZYDUS LIFESCIENCES LIMITED (0.8%), SAVA HEALTHCARE LIMITED (0.5%).
Top Fluticasone Exporters from India
Ranked by export value · 239 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED DYMISTA NASAL SUSPENSION);DYMISTA TRADE PACK -SALPLUSF INHALER 250/25APO-FLUTICASONE HFA 250MCG/MD(WITH POUCH | $184.7M | 53 | 91.0% |
| 2 | HETERO LABS LIMITED FLUSACORT SALMETEROL+FLUTICASONE PROPIONATE INHALERAURITUSS INHALERFLUSACORT SALMETEROL +FLUTICASONE PROPIONATE INHALER | $4.5M | 4 | 2.2% |
| 3 | MEDISPRAY LABORATORIES PRIVATE LIMITED SEROFLO 250 HFA INHALERFLOHALE 250 HFA INHALER FLUTICASONE PROSEROFLO 125 HFA INHALER | $2.6M | 1 | 1.3% |
| 4 | ZYDUS LIFESCIENCES LIMITED | $1.7M | 8 | 0.8% |
| 5 | SAVA HEALTHCARE LIMITED | $1.1M | 7 | 0.5% |
| 6 | VAMSI PHARMA PRIVATE LIMITED DYMISTA TRADE PACK 17ML/120 MD DYMFLUTICASONE & SALMETEROL INHALATION POWDER | $1.1M | 2 | 0.5% |
| 7 | MIDAS CARE PHARMACEUTICALS PVT LTD | $730.9K | 2 | 0.4% |
| 8 | LAWRENCE WALTER SALMETEROLO E FLUTICASONE DOC 25+250 MCGSALMETEROLO E FLUTICASONE DOC 25+125 MCGSALMETEROL /FLUTICASONE CIPLA 25/250MG I | $557.7K | 3 | 0.3% |
| 9 | PRIME PHARMACEUTICALS PRIVATE LIMITED | $453.4K | 3 | 0.2% |
| 10 | AVALOR HEALTH CARE PRIVATE LIMITED | $438.1K | 1 | 0.2% |
| 11 | CADILA HEALTHCARE LIMITED | $318.5K | 4 | 0.2% |
| 12 | MARYUS HEALTHCARE PRIVATE LIMITED | $313.7K | 1 | 0.2% |
| 13 | MARKSANS PHARMA LIMITED SEROFLO 250 HFA INHALERFLOHALE 250 HFA INHALER FLUTICASONE PROSEROFLO 125 HFA INHALER | $290.0K | 3 | 0.1% |
| 14 | LLOYD LABORATORIES PRIVATE LIMITED | $276.2K | 1 | 0.1% |
| 15 | PLEASANT EXPORTS | $246.7K | 3 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Fluticasone exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Warning Letter (November | Yes | Yes | 276 | Received FDA warning letter for Pithampur facility in November 2023. |
| HETERO LABS LIMITED | Approved | Yes | Yes | 303 | Hetero Labs has received approvals from US FDA, WHO-GMP, and EU GMP. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | Unknown | Zydus Lifesciences has received approvals from US FDA, WHO-GMP, and EU GMP. |
| SAVA HEALTHCARE LIMITED | Approved | Yes | Yes | Unknown | Sava Healthcare has received approvals from US FDA, WHO-GMP, and EU GMP. |
| MIDAS CARE PHARMACEUTICALS PVT LTD | Approved | Yes | Yes | Unknown | Midas Care Pharmaceuticals has received approvals from US FDA, WHO-GMP, and EU G |
| MARKSANS PHARMA LIMITED | Approved | Yes | Yes | Unknown | Marksans Pharma has received approvals from US FDA, WHO-GMP, and EU GMP. |
| CADILA HEALTHCARE LIMITED | Approved | Yes | Yes | Unknown | Cadila Healthcare has received approvals from US FDA, WHO-GMP, and EU GMP. |
| PLEASANT EXPORTS | Approved | Yes | Yes | Unknown | Pleasant Exports has received approvals from US FDA, WHO-GMP, and EU GMP. |
TransData Nexus reviewed the regulatory standing of 8 leading Fluticasone exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Fluticasone sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma Capital of India," is a leading center for bulk drug manufacturing, accounting for approximately 40% of the country's bulk drug production. The city hosts over 2,000 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, a premier biotech cluster, further enhances Hyderabad's capabilities in pharmaceutical research and development.
The establishment of Hyderabad Pharma City, envisioned as the world's largest integrated pharmaceutical hub, underscores the city's commitment to advancing pharmaceutical manufacturing and innovation.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes 33% to India's drug manufacturing and 28% to drug exports, with Ahmedabad and Vadodara being pivotal hubs. Notable companies such as Zydus Lifesciences Limited and Alembic Pharmaceuticals are headquartered here, specializing in the production of finished dosage forms.
Vadodara, in particular, has a rich history in the pharmaceutical sector, being home to Alembic Pharmaceuticals, established in 1907. The city's strategic location and industrial infrastructure make it a key player in the formulations segment.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Mumbai, being India's financial capital, offers robust infrastructure and connectivity, facilitating the export of pharmaceuticals to global markets. The region hosts several pharmaceutical giants, including Cipla Limited, which holds a significant share in Fluticasone exports.
The proximity to major ports and international airports enhances the region's capacity to handle large-scale exports efficiently, making it a strategic location for companies aiming to serve international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing hub, primarily due to favorable tax incentives offered by the government. This zone attracts numerous pharmaceutical companies seeking cost-effective production facilities.
The region's growth is supported by a conducive business environment and infrastructure, making it an attractive destination for pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: While Cipla Limited dominates Fluticasone exports, consider engaging with other manufacturers such as Hetero Labs Limited and Zydus Lifesciences Limited to mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad's capabilities for bulk drug procurement and Ahmedabad-Vadodara's expertise in formulations to optimize sourcing strategies.
- Assess Export Logistics: Evaluate the logistical advantages of the Mumbai-Thane-Raigad region for efficient export operations, ensuring timely delivery to international markets.
- Monitor Regulatory Compliance: Stay informed about regulatory standards and certifications in each cluster to ensure compliance and maintain product quality across the supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Fluticasone exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' U.S. biologics manufacturing facilities
Zydus Lifesciences Limited completed the acquisition of Agenus Inc.'s biologics manufacturing facilities in the United States, establishing a new subsidiary, Zylidac Bio LLC, to provide contract development and manufacturing organization (CDMO) services globally. IMPACT: This acquisition enhances Zydus' manufacturing capabilities, potentially increasing Fluticasone production capacity.
Impact: This acquisition enhances Zydus' manufacturing capabilities, potentially increasing Fluticasone production capacity.
Zydus Lifesciences Limited — Zydus acquires 50% stake in Sterling Biotech Limited
Zydus Lifesciences Limited acquired a 50% equity stake in Sterling Biotech Limited, a company specializing in gelatin, di-calcium phosphate, and select active pharmaceutical ingredients, marking Zydus' entry into specialized biotech products for health and nutrition. IMPACT: This strategic move may diversify Zydus' product portfolio, indirectly affecting Fluticasone production.
Impact: This strategic move may diversify Zydus' product portfolio, indirectly affecting Fluticasone production.
Zydus Lifesciences Limited — Zydus enters medical devices market with Amplitude Surgical acquisition
Zydus Lifesciences Limited acquired 85.6% of France-based Amplitude Surgical for €256.8 million, marking its entry into the medical devices segment, particularly in lower-limb orthopedic implants. IMPACT: This diversification may lead to resource reallocation, potentially impacting Fluticasone production focus.
Impact: This diversification may lead to resource reallocation, potentially impacting Fluticasone production focus.
Common Questions — Fluticasone Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which fluticasone supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 2,663 recorded shipments worth $184.7M. HETERO LABS LIMITED (112 shipments) and MEDISPRAY LABORATORIES PRIVATE LIMITED (19 shipments) are also established high-volume exporters.
Q How many fluticasone manufacturers are there in India?
India has 239 active fluticasone exporters with a combined export market of $203.0M across 9,009 shipments to 123 countries. The top 5 suppliers hold 95.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for fluticasone from India?
Average FOB unit price: $17.14 per unit, ranging from $0.01 to $3871.76. Average shipment value: $22.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 239 verified Indian exporters of Fluticasone ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 9,009 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 123 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
9,009 Verified Shipments
239 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists